Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
~37~'8 24205-674
This application is closely related to Serial No.
470,382 filed December 18, 1984.
This invention relates to ascorbic acid derlvatives
useful for prophylaxis and improvement of disorders in the
circulatory system, a method for producing them and
pharmaceutical compositions containing same.
Diseases of heart, brain, kidney, etc., which are
often observed in adults, are mainly caused by disturbances
and destruction of cells or tissues due to ischemia as a
basal pathologic state, to result in hemostasia leading to
suspension of supplying energy source. The morbidity rate
of, for example, ischemic heart diseases, ischemic cerebral
diseases, ischemic renal disturbances, ischemic gastro-
intestinal ulcers, has recently increased with the develop-
ment of highly civilized society, and or the society holding
high rates of persons of advanced age, and these diseases
have become major factors in mortality rate in advanced
countries.
Recently, it has been revealed that biologically
activated oxygen species or reactive organic radical
species play an important role in aggravation of lesions
in ischemic tissues (i.e. lowering of cell function, dis-
turbances, destruction, necrosis of cells, etc.)
~`
541370
.
1~3~7'~E~
--2--
[I. Fridovich, Annual Review of Pharmacology and Toxicology23, 239 (1983); J. M. McCord, The New England Journal of
Medicine, 312, 159 (1985); K. P. Burton, J. M. McCord and
G. Ghai, American Journal of Physiology, 246, H776 (1984)].
As the active oxygen species or reactive organic radical
species in living system are considered, among others, super-
oxide anion radical (2)~ hydroxyl radical (.OH), singlet
oxygen ( 2)~ and pero~ide radical (ROO.). Especially,
relationship between the formation of 2 in a living system
and the subsequent damages of cells or tissues caused by the
reactive oxygen specis~shave impor~nt meanings in ischemic disorders.
Especially, it is considered that excess generation
f 2 in developing tissue damages after blood
reperfusion at the site of ischemic lesion or after
ischemia has an important significance.
It has been known that superoxide dismutase effectively
acts to scavengeO2 specifically,protects asainst tissue damages and
alleviates tissue disturbances after reperfusion of the
site of ischemia or after ischemia [D. N. Granger,
G. Rulili, J. M. McCord, Gastroenterotogy, 81, 22 (1981)].
Also, it has been reported that such compounds as ascorbic
acid, ~-tocopherol, cysteine and reduced glutathione have
an activity to scavenge free radicals, and that these
compounds could prevent lesions in tissues, which are seemed
to be caused by free radicals in pathological conditions
37~
--3--
[I. Fridovich, Science, 201, 875 (197~)].
Based on the fundamental studies so far made, revealing
that reactive oxygen species and organic radicals play a
significantly important role in causing tissue disturbances
in a living system, the present inventors have conducted
research wor~ for finding out a novel type of pharmaceuticals
excellent pharmacologically as well as pharmaceutically
aiming at scavenging reactive oxygen species and organic
radicals. As the result, the present inventors found that
2-O-substituted ascorbic acid derivatives and homologs
thereof showed, in experiments in vitro and in various
animal test models, strong actions to scanvenge reactive
oxygen species and organic radicals, and that they controlled
ischemic heart diseases, distrubances in cerebral function
or renal disorders, thus accomplishing the present invention.
The present invention relates to
a pharmaceutical composition for prophylaxis and improvement
of disorders in functions of the circulatory system, which
contains an ascorbic acid derivatives of the formula;
R -~0 ~ [I]
H0 0-R'
1~9;~'7;~
--4--
[wherein Rl stands for an organic residue having a molecular
weight of from 15 to 700; R2 stands for hydrogen or hydroxyl
group; and R3 stands for hydrogen, acyl group, an optionally
substituted phosphono group or sulfo group, and
R3 and the hydroxyl group of R2 may form acetal residue or
ketal residue],or a salt thereof, and a pharmaceutically
acceptable carrier, vehicle or diluent therefor,
an ascorbic acid derivatives representable by the formula;
~3 - o
O~ [:~ ]
~0 0--~1
[wherein Rl stands for an organic residue having a molecular
weight of from 15 to 700; R2 stands for hydrogen or hydroxyl
group; and R3 stands for hydrogen, acyl group or an optionally
substituted phosphono group, and R3 and hydroxyl group of
R2 may form acetal residue or ketal residue, provided that
Rl is other than an organic residue having a molecular weight
of from 15 to 400 exclusive of substituted benzyl, phenacyl,
cycloalkylmethyl and C1_22 alkyl which is substituted with
hydroxyl or benzyloxy, when R2 is hydroxyl group and R3 is
hydrogen]; or a salt thereof,
3'i~
a method for producing an ascorbic acid derivative
representable by the general formula;
~0
~ ~
[Ia]
~0 0-R'
[wherein Rl stands for other than an organic residue having
a molecular weight of from 15 to 400 exclusive of substituted
benzyl, phenacyl, cycloalkylmethyl a,nd Cl-22 alk~l which is
substituted with hydroxy or benzyloxy] or a salt thereof,
characterized by subjecting a compound representable by the
formula;
X { ~ ~
~ ~ 0
)=( [m]
R~-0 0-R'
[wherein Rl is as defined above; R4 stands for a group
Cleavable by hydrolysis or reduction; and X stands for two
hydrogens, acetal residue or ketal residue] to hydrolysis
or acid hydrolysis, followed by reduction,
a method for producing an ascorbic acid derivative
representable by the general formula;
1~3'7~
--6--
R5 R2~
[Ib]
~0 0-R'
[wherein Rl and R2 are as defined above; and R5 stands for
acyl or optionally substituted phosphono]
characterized by subjecting an ascorbic acid derivative
representable by the general formula;
~R2 ~
~0
~ [IV]
~0 0-R'
[wherein Rl and R2 are as defined above]
to acylation or phosphorylation, and in
case of acylation being conducted, followed by, when
necessary, acyl migration or deacylation,
a method for producing an ascorbic acid derivative
representable by the formula;
1~3'7~3
~o
[Ic]
H0 0_~l
[wherein Rl is as defined above],
characterized by subjecting a compound representable by
the formula;
1~8{_ oO =~
~ [V]
~--0 0--~'
[wherein Rl and R4 are as defined above; and R6 stands
for acetal résidue, ketal residue or O=S< group] to
dehydration, then reduction, followed by, when necessary,
hydrolysis, and
a method for producing an ascorbic acid derivative
representable by the formula;
1~3';'~f~
--8--
X~{_0 ~ [Id]
~0
~0 0-B'
[wherein X' stands for acetal residue or ketal residue, and
Rl is as defined above] characterized
by subjecting an ascorbic acid derivative representable by
the formulai
H0
H0 ~ [Ia]
HO O-B'
[wherein Rl is as defined above] to
acetalization or ketalization.
In the above general formulae, the organic residue
having a molecular weight of from 15 to 700 as represented
by Rl includes, for example, straight-chain or branched
alkyl groups optionally having substituents.
The above straight-chain or branched alkyl groups
having a molecular weight of from 15 to 700 optionally
having substituents is preferably that having 1 to 22
carbon atoms, more preferably 9 to 20 carbon atoms,
further preferably straght-chain aIkyl grou~ having 14 to 20 carbon atoms.
1~53';';~
Examples of such alkyl group include methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, n-pentyl, n-hexyl, n-heptyl,
n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl,
n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl,
n-octadecyl, n-nonadecyl, n-eicosyl, n-heneicosyl and
n-docosyl.
The number of methylene groups in the straight-chain or
branched substituted alkyl group having a molecular weight
of from 15 to 700 is preferably l~ 22.
The substituents of the above alkyl group are exemplified
by optionally substituted hydroxyl groups, optionally sub-
stituted amino groups, optionally substituted carboxyl groups,
optionally substituted aminocarbonyl groups, optionally
substituted vinyl groups, optionally substituted ethynyl
groups, optionally substituted cycloalkyl groups, optionally
substituted aryl groups, optionally substituted heterocyclic
groups, quinoyl representable by
C~I3
Ca3 ~ or chnx~n-2-yl ~ OH
-C~ ~ Rq representable by ~7
[wherein R7 stands for methyl group, methoxy group, and the
two R7's form -CH=CH-CH=CH- group; and R8 stands for phenyl,
naphthyl, thienyl or pyridyl].
1~3'7~'~
- 10 -
As the optionally substituted hydroxyl groups are
mentioned those representable by the formula; -O-R9-
[wherein R9 stands for hydrogen, Cl 3 alkyl or phenyl].
As the optionally substituted amino groups are mentioned
those representable by the formula; -N-Rll [wherein RlO and
R independently stand for hydrogen, C1 3 alkyl, phenyl or
p-hydroxyphenyl]. As the optionally substituted carboxyl
groups are mentioned those representable by the formula;
-CO-O-Rl2 [wherein Rl2 stands for hydrogen, Cl 3 alkyl or
phenyl]. As the optionally substituted aminocarbonyl groups
are mentioned those representable by the formula; -Co-NH-Rl3
[wherein Rl3 stands for hydrogen, Cl 3 alkyl, phenyl or
p-hydroxyphenyl]. As the optionally substituted vinyl
groups are mentioned those representable by the formula;
15 -CH=CRl5 [wherein R14 and R15 independently hydrogen,
phenyl, p-methoxyphenyl, 3-pyridyl or 3,4-methylene
dioxyphenyl]. As the optionally substituted ethynyl groups
are mentioned those representable by the formula; -C_C-Rl6
[where in Rl6 stands for Cl 6 alkyl].
The cycloalkyl group in the optionally substituted
cycloalkyl groups is preferably those of C3 6' exemplified
by cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The
cycloalkyl may optionally have 1~ 3 substituents exemplified
by carboxyl, hydroxyl or Cl 6 alkyl. Examples of the
optionally substituted aryl group include a group representable
by the formula;
lZ93~ ~8
- 11 - 24205-674
R17
__~ Rl 8
Rl9
[wherein R17, R18 and Rl9 independently stand for hydrogen, Cl_3
alkyl, Cl_6 alkoxy, halogen, ethoxycarbonylethenyl, phenyl,
carboxyl, Cl_3 alkoxy-carbonyl or l-carboxyethyl] or naphthyl
optionally substituted with 1 to 3 of Cl_3 alkyl, Cl_3 alkoxy,
halogen, carboxy or acetyl.
The Cl_6 alkyl is exemplified by methyl, ethyl, n-
propyl, isopropyl, n-butyl, n-pentyl or n-hexyl.
The Cl_3 alkyl is exemplified by methyl, ethyl, n-propyl
or isopropyl.
The Cl_3 alkoxy is exemplified by methoxy, ethoxy, n-
propoxy or isopropoxy.
The halogen is exemplified by chlorine, bromine,
fluorine or iodine.
Examples of the hydroxyl group having the said substi-
tuent include Cl_3 alkoxy of methoxy, ethoxy, propoxy, isopropoxy
and phenoxy. Examples of the amino group having the said substi-
tuent included mono Cl_3 alkyl or di Cl_3 alkyl of methylamino,
dimethylamino, ethylamino, propylamino, isopropylamino, phenyl-
amino and p-hydroxyphenylamino. Examples of the carboxyl group
having the said substituent include methoxycarbonyl, ethoxy-
carbonyl and
~'~
3';~
-12-
phenoxycarbonyl. Examples of the aminocarbonyl group
having the said substituent include methylaminocarbonyl,
dimethylaminocarbonyl, isopropylaminocarbonyl, phenyl-
aminocarbonyl and p-hydroxyphenylaminocarbonyl.
Examples of the vinyl group having the said substituent
include propenyl, butenyl, pentenyl, hexenyl, heptenyl,
l,l-diphenylethenyl, l-phenyl-l-(3-pyridyl)ethenyl and
l-phenyl-l-(2-thienyl)ethenyl. Examples of the ethynyl
group having the said substituent include methylethynyl,
ethylethynyl and n-pentylethynyl. Examples of the cycloalkyl
group having the said substituent include cyclopropyl,
cyclopentyl, cyclohexyl, l-carboxycyclopropyl, 2-carboxycyclo-
propyl, l-carboxycyclopentyl, l-carboxycyclohexyl and
4-carboxycyclohexyl. Examples of the aryl group having
the said substituent include phenyl, 1- or 2-naphthyl, 2-,
3- or 4-monomethylphenyl, 2-, 3- or 4-monomethoxyphenyl, 2-,
3- or 4-monomethoxyphenyl~ 2-, 3 or 4-monohalogenophenyl
(halogen atom means chlorine, bromine or fluorine atom),
2,3-methylenedioxyphenyl, 3,4-dimethylphenyl, 3,4-
dimethoxyphenyl, 4-(ethoxycarbonylethenyl) phenyl, 4-
isopropylphenyl, 4-methoxycarbonylphenyl, 3,4,5-trimethylphenyl,
3,4,5-trimethoxyphenyl, 4-biphenyl, 4-carboxyphenyl, 4-
carboxymethylphenyl, and 4-(1-carboxyethyl)phenyl. Examples
of the heterocyclic group having the said substituent
25 include 2-, 3- or 4-pyridyl, 2- or 3-thienyl, morpholine,
pyrrolidinyl, piperidinyl, piperazinyl, 4-phenylpiperazinyl,
1~3'7~
-13-
4-(p-flurophenyl)piperazinyl, 4-diphenylmethylpiperazinyl and
4-(p-methoxyphenyl)piperazinyl, which may have 1-3 substituents
exemplified by Cl 3 alkyl, carboxyl, hydroxyl group, phenyl,
halogen, carboxymethyl or benzoyl.
In the above-mentioned general formulae, the organic
residue having a molecular weight of from 72 to 700 as
represented by Rl includes, for example, straight-chain or
branched alkyl groups optionally having substituents.
The alkyl group in the said optionally substituted
lO straight-chain or branched alkyl groups having the molecular
weight of from 72 to 700 is preferably those whose carbon
number is from 6 to 22, more preferably those whose carbon
number is from ll to 20, as exemplified by n-hexyl, n-heptyl,
n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl,
15 n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-
octadecyl, n-nonadecyl, n-eicosyl, n-heneicosyl, n-docosyl,
etc.
The number of methylene groups in the above-mentioned
straight-chain or branched substituted alkyl group having a
20 molecular weight of from lS to 700 is preferably l~ 22.
As the substituents in the said substituted straight-
chain or branched alkyl group having a molecular weight of
from 72 to 700, are mentioned the same substituents in the
afore-said optionally substituted straight-chain or branched
25 alkyl group having a molecular weight of from 15 to 700.
1~t3'7~3
-14-
The acyl group representable by R3 and R5 in the above
general formulae include straight-chain or branched fatty acid
whose carbon number is 1 ~ 22, optionally substituted
benzoic acid, optionally substituted thienylacetic acid,
optionally substituted phenylacetic acid, dicarboxylic acid,
acyl groups derivable from carboxylic acid representable by
the formulae;
CH3 0
8 ~_ 0~ `-(CH2)~,COOH or 8 ~ C~(CH2)m2COOH
[wherein R7 and R8 are as defined above, m, denotes an integer
of 1 or 2 and m2 denotes an integer of 2 to 8] or an optionally
substituted aminocarbonyl group.
Examples of the fatty acid include Cl_20 fatty acid of formic acid,
acetic acid, propionic acid, valeic acid, butyric acid, hexanoic
acid, heptanoic acid, octanoic acid, nonanoic acid,
decanoic acid, undecanoic acid, tridecanoic acid, tetradecanoic
acid, pentadecanoic acid, hexadecanoic acid, octadecanoic acid,
nonadecanoic acid,eicosanoic acid, isopropionic acid, etc.
Examples of the substituents of the said optionally
substituted benzoic acid include Cl 3 alkyl, Cl 3 alkoxy,
methylenedioxy, halogen, etc.
'7~
-15-
The substituent of the optionally substituted 2- or 3-
thienyl acetic acid is exemplified by Cl 3 alkyl. Examples
of the substituent of the optionally substituted phenyl
acetic acid include Cl 3 alkyl, Cl 3 alkoxy, methylenedioxy,
halogen, etc. The substituents of the optionally substituted
phenyl group thienyl group or naphthyl group representable
by R17 are exemplified by Cl 3 alkyl, Cl 3 alkoxy,
methylenedioxy, halogen, etc. The substituent of the said
optionally substituted aminocarbonyl group is exemplified by
optionally mono- or di-substituted Cl 6 lower alkyl group
or monophenyl group. Examples of the Cl 6 lower alkyl group
include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
n-pentyl, n-hexyl, etc. The substituents are exemplified
by phenyl, naphthyl, pyridyl, imidazolyl, etc.
As the acyl group derivable from dicarboxylic acid
is mentioned those of monoester type. Examples of the
dicarboxylic acid include malonic acid, succinic acid,
glutaric acid, adipic acid, etc.
As the said Cl 6 lower alkyl are exemplified
methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl,
n-hexyl, etc.
As the said Cl 3 alkyl are exemplified methyl, ethyl,
n-propyl, isopropyl, etc.
As the said alkoxy are exemplified methoxy, ethoxy,
n-propoxy, isopropoxy, etc.
1~?3'~
-16-
As the said halogen are exemplified chlorine,
bromine, iodine and fluorine. In the above formulae,
the substituents at the optionally substituted phosphono
group as represented by R3 are preferably mono-substituted
ones which are exemplified by those representable by the
formula -(CH2)n-R24 [wherein n denotes an integer of l- 3
and R24 stands for a heterocyclic group having amino,
dialkylamino, trialkylamino or nitrogen].
Preferabie examples of the alkyl at the dialkylamino
and trialkylamino as represented by R24 are methyl, ethyl,
n-propyl and isopropyl.
As the nitrogen-containing heterocyclic ring as
represented by R24 are exemplified l-pyridinio, l,3-
thiazolinio, piperazinyl, piperidino, morpholino,
pyrrolidinyl, etc.
In the above general formula, examples of the
cleavable groups by hydrolysis as represented by R4 are
methoxymethyl, ethoxymethyl, benzyloxymethyl, 2-
tetrahydropyranyl, trimethylsilyl, dimethyl tertiary
butylsilyl, etc., and examples of the cleavable groups
by reduction as represented by R4 are benzyl, p-methoxybenzyl,
etc.
As the above-mentioned acetal residue, groups
representable by the formula R2l-CH~ [wherein R2l stands
for Cl 3 alkyl, phenyl or p-methoxyphenyl] are mentioned,
and, as the ketal residue, groups representable by the
formula R23> C< [wherein R22 and R23 independently stand
-17~ 3 7~8
for hydrogen or Cl 3 alkyl, or R22 and R23 form -(CH2)a-
(wherein a denotes 4 or 5)] are mentioned.
Examples of the above-mentioned Cl 3 alkyl include
methyl, ethyl, n-propyl or isopropyl.
In case where Compound [I] or [II] is capable of
forming a salt, it may be formed into a salt, and the
salt is exemplified by inorganic salt of sodium salt, potassium salt,
ammonium salt, hydrochloride, sulfate, etc., or it may
form an internal salt.
Compound [Ia] i.e. Compound [I] wherein R2 is
hydroxyl group and R3 is hydrogen, when the~protecting
group in Compound [III] is cleavable by hydrolysis, can
be produced by subjecting Compound [Ia] to acid hydrolysis
to remove the acetal residue or ketal residue at the 5-,
and 6-positions and the protecting group at the 3-position
simultaneously.
In case where the protecting group R4 at the 3-
position of Compound [III] is cleavable by reduction,
Compound [Ia] can be produced by subjecting Compound [III]
to acid hydrolysis to remove the acetal residue or ketal
residue at the 5,6-position, followed by removing the
protecting group at the 3-position by catalytic reduction.
Compound [Ib], i.e. Compound [I] wherein R3 is
acyl group, can be produced by subjecting Compound [IV], i.e.
Compound [I] wherein R3 is hydrogen, to acylation, or,
when a compound representable by the general formula;
1~3~
-18-
~0--
R 2~ [ Vl
R5-0 0-~'
[wherein Rl, R2 and R5 are as defined above, and R5 stands
for acyl group] is produced by the acylation, by further
subjecting the compound to acyl-rearrangement reaction.
Compound [Ic], i.e. Compound [I] wherein R2 and R3 are
both hydrogen, can be produced by subjecting Compound [V]
to hydrolysis under basic conditions, followed by catalytic
reduction and, when necessary, acid hydrolysis.
The above acid hydrolysis is carried out for about
1-2 hours at about 10-80C in water or an organic solvent
e.g. methanol, ethanol, dioxane, tetrahydrofuran, 1,2-
dimethoxyethane, or an aqueous mixture thereof.
The above catalytic reduction is carried out for
20 about 4-10 hours at about 10C-100C in an organic solvent
e.g. methanol, ethanol, ethyl acetate, dioxane, 1,2-
dimethoxyethane, etc., in the presence of, for example,
palladium, palladium-carbon, platinum black, palladium
chloride, platinum oxide, etc.
In the above acylation, as the reactivity of the
enolic hydroxyl group at the 3-position is higher than
1~37 ~8
,9
that at the 6-position, the former hydroxyl group is first
acylated. The 3-O-acyl derivative is, depending on the
kinds of acyl group, readily rearranged internally under
weakly basic conditions, to lead to a 6-O-acyl derivative
[VI]. 3-O-Acyl derivative [VI] exists as an intermediate
as well, but it is readily susceptible to internal
migration or hydrolysis, thus being chemically unstable
compound. Accordingly, a 6-O-acyl derivative can be produced
by subjecting a 3-O-acyl derivative to internal migration.
The internal migration completes in about 1-10
hours at about 20-100C in the presence of a weak base [e.g.
pyridire, sodium carbonate, buffer solution (pH about 7-8)].
The above acylation is usually conducted by a con-
ventional method. As the solvent is often used acid chloride
or anhydride of carboxylic acid ~including mixed acid
anhydride), and the reaction is carried out in the presence
of a base e.g. pyridine, triethylamine, potassium carbonate,
sodium carbonate, sodium hydrogencarbonate, etc., at about
-10 - 50C. The reaction time is, in most cases, within
about 1-10 hours.
In the above phosporylation, the phosphorylating agent
to be employed is exemplified by 2-cyanoethylphosphate-
dicyclohexylcarbodiimide, di-p-nitrobenzylphosphorylchloride,
dioxane diphosphate, dimorpholyl phosphoric acid chloride,
pyrophosphoryltetrachloride, etc.
1~3'7~8
-20-
In the a~ove sulfonation, the surfonating agent to be
employed is exemplified by sulfuric anhydride (SO3), sulfuric
anhydride pyridine (S03-C5H5N), sulfuric acid dioxane
(SO3OC4H8O), sulfuric anhydride dimethylformamide
[S03-HCON(CH3)2], sulfuric anhydride triethylamine
[S03-N(C2H5)3], etc.
In the above phosphorylation and sulfonation, the
solvent to be employed is exemplified by dioxane, dimethyl-
formamide, chloroform, methylene chloride, etc. The
reaction temperature is within the range of from -10C to
-50C, and the reaction time is about 1-10 hours. To lead
the compound obtained to a salt thereof, a
conventional means is employed. Elimination of the acyl
group at the 3-position is conducted by the addition of an
equimolar amount of sodium hydrogencarbonate or pyridine,
and hydrolysis is conducted at room temperature.
The reaction time is about 1-6 hours.
The dehydration is completed in about 1-4 hours at a
temperature range of about 30-80C in an organic solvent
such as methylene chloride, chloroform, dioxane,
tetrahydrofuran, benzene, etc., in the presence of an
organic base e.g. l,S-diazabicyclo[4,3,0]-5-nonene, 1,4-
diazabicyclo[2~2~2]octane~ 1,8-diazabicyclo[5,4,0]-7-undecene,
pyridine, triethylamine.
By conducting the dehydration, a compound of the general
formula [VI'];
1~37~8
-21-
~0
~ [VI']
R~-0 0-RI
[wherein Rl and R4 are as deflned above] can be obtained.
By subjecting . compound [VI'] to reduction, followed
by, when necessary, hydrolysis, Compound [Ic] can be produced.
The said reduction and hydrolysis can be conducted as
mentioned above.
The reaction for producing Compound [Id] by
acetalization or ketalization of Compound [Ia] is conducted
by allowing the starting compound to react with ketone or
aldehyde, e.g. acetone, benzaldehyde, cyclopentanone,
cyclohexanone, etc. As the reaction solvent are employed
toluene, tetrahydrofuran, chloroform, diethylether,
dichloromethane, dichloroethane, etc. The reaction
temperature ranges from about 15C to 150C, and the
reaction is conducted in the presence of an acid catalyst.
The catalyst is exemplified by acetylchloride, sulfuric
acid, p-toluenesulfonic acid, camphorsulfonic acid. The
reaction time ranges from about 1 to 24 hours.
Thus produced ascorbic acid derivatives [I] can be
separated and collected by per se known separation and
purification means (e.g. column chromatography using
1~t3'7;~
-22-
silica-gel, polystyrene resins, activated carbon, reverse
phase system, etc., recrystallization, etc.).
Compounds employable as the starting materials in the
method of this invention can be produced by, for example,
the following reaction steps.
[A] - Method for producing Compound [m '], i.e.
Compound [m] wherein ~ is acetal or ketal residue, and
Compound [V'], i.e. Compound [V] wherein R6 is acetal
residue or ketal residue:
HO
HO ~ {Ascorbic acid, d,Q-ascorbic acid,
1S HO OH isoascorbic acid
Acetaliza-
tion,
ketaliza-
\ tion
R~ X'{-8 ~
1~ [VI[]
HO OH
¦R~ Y
\ /
2s
1~3~7~
-23-
~8', ~('{- 8 -~
[vm ]
R~ O 0
¦RI--Z
RB' .X'{-8~
~~' [V'], [1:~]
/\=\
R~ O O~R
In the above formulae, X' and R6 stand for acetal
or ketal residue.
1~3'7~'~
-24-
In case of ascorbic acid being used as the startlng
material, the ascorbic acid is first acetalized or ketalized
to produce Compound (V~ ]. This reaction is conducted by
allowing ascorbic acid to react with ketone or aldehyde e.g.
acetone, benzaldehyde, cyclopentanone, cyclohexanone, etc.
As the reaction solvent are employed, among others,
tetrahydrofuran, chloroform, diethylether, dichloromethane
or dichloroethane. The reaction temperature ranges from
room temperatures to 60C, and the reaction is conducted
in the presence of an acid catalyst. Examples of the
catalyst include acetylchloride, sulfuric acid, p-
toluenesulfonic acid and camphorsulfonic acid. The reaction
time ranges from 4 to 24 hours. Subsequently, Compound
[V~ ] is allowed to react with a compound representable
by the formula; R4-Y [wherein R4 is as defined above, and Y
stands for halogen (e.g. chlorine, bromine)] (e.g. chloromethyl-
methylether, chloromethylethylether, benzylchloride,
benzylbromide) in dimethylformamide, dimethylsulfoxide
(DMSO), hexamethylphosphoramide or tetrahydrofuran, either
2a singly or a solvent mixture thereof in the presence of an
inorganic base such as potassium carbonate, sodium carbonate,
sodium hydroxide, potassium hydroxide and sodium hydrogen-
carbonate to produce Compound (V m]. The reaction temperature
ranger from 0C to 40C (preferably 25C). The reaction
goes to conclusion within 1 to 18 hours.
1~93'7~
Then, Compound (V m] thus obtained is allowed to
react with a compound representable by the formula; Rl-Z
[wherein Rl is as defined hereinbefore, and Z stands for
halogen (e.g. chlorine, bromine)] in a solvent such as
dimethylformamide, dimethylsulfoxide, hexamethyl-
phosphoramide or tetrahydrofuran, solely or as a solvent
mixture thereof, in the presence of an inorganic base
(e.g. sodium hydroxide, po~assium hydroxide, sodium carbonate
and potassium carbonate) at a temperature of 10 to 60C
for 1 to 18 hours to produce Compound ~m ~ ] or [V'].
Compound [m "], i.e. Compound (m] wherein X stands
for two hydrogen atoms, can be produced by subjecting
Compound [m '] to hydrolysis similar to that mentioned
hereinbefore.
[B]-Compound [m "], e.e. Compound [m] wherein X is two
hydrogen atoms, can be produced by the following process.
Ascorbic acid
~ {Isoascorbic acid
HO OH
1R'-Y
HO--
~ [IX]
~
R'-O OH
1~3'7,
- 26 -
R'--Z
HO
S ~o=~j O\,~
~ [m~ ~ ], [x]
B~--O O--R'
In the above method, ascorbic acid or isoascorbic
acid is employed as the starting material, and the
hydroxyl group of its 3-position is allowed to react, in
accordance with the conventional method, with methoxymethyl
chloride, ethoxymethyl chloride, benzylbromide,
trimethylsilyl chloride, dimethyl tertiary silyl chloride,
etc. to give a 3-0-ether compound (IX], then, thus
obtained compound [IX] is allowed to react with a compound
representable by the formula; Rl-Z [wherein Rl and Z are
as defined hereinbefore] within the temperature range
of about 10~ 60C for about 1 to 20 hours in dimethyl-
formamide, dimethylsulfoxide, hexamethyl phosphoramide,
tetrahydrofuran, dioxane, etc., either singly or as a
solvent mixture, in the presence of an inorganic base
(e.g. potassium carbonate, sodium carbonate, etc.) to
give Compound [X].
[C]- Method for producing Compound [V'], i.e.
Compound [V] wherein R6 stands for O=S~ group:
1'~937~
The above compound is produced by allowing thionyl
chloride to react with Compound [X].
The reaction is carried out in a solvent, for example
tetrahydrofuran, dimethylformamide, methylene
chloride, etc. in the presence of an organic base, for
example, triethylamine, pyridine, 1,8-diazabicyclo[5,4,0]-
7-undecene. The reaction is conducted at about 0~ 30C for
about 1~ 6 hours.
Compounds [ m ] and [V] as produced in accordance with
the afore-mentioned methods are useful as intermediates
for the synthesis of, for example, Compound [I].
Compound [I] and salts thereof show lipid per-oxidation
inhibitory action in the experiments in vitro employing a
stable radical or brain homogenates, and, in the
ischemia-reperfusion model in the heart of rats or the
ischemic brain model in rats or the renal failure
model in rats due to oxygen free radicals,they show
actions of preventing or improving the respective
functional disorders, while they show remarkably low
toxicity and no side effects. Compound
[I] and salts thereof show therapeutic, prophylactic and
improving actions against various functional disorders, for
example, ischemic heart diseases (arrhythmia, coronary vaso_
spasm, necrosis of cardiac tissue, myocardial infarction,
etc.), subarachnoidal hemorrage, ischemic disorders of
cerebral tissue (e.g. cerebral infarction, dementia,
1~3'~ ~
-28-
senile dementia, etc.), ischemic renal disorders,
intestinal ischemic (e.g. intestinal ulcer, etc.), thus
being useful as preventing and improving agents of functional
disorders in the circulatory svstem.
Specific examples of the use as the above preventing and
improving agents of functional disorders in the circulatory
system include improving agents of circulatory system,
improving agents of renal functions, therapeutic agents
of stress intestinal ulcer, etc., e.g. agents of anti-
arrhythmia, anti-myocardiac infarction, anti-cerebral
infarction, preventing senile dementia, therapv
and improvement after subarachmoidal hemorrhage.
The compounds of this invention are low in toxicity (e.g.
in acute toxicity to mice, no test animals were killed by
oral administration at a dose of 1000 mg/kg), and
Compound [I] can be safely administered orally or non-
orally as pharmaceutical compositions [e.g. tablets, capsules
(including soft-capsules and micro-capsules), liquids,
suppositories, injections, preparations for nasal
inhalation] prepared by mixing with per se conventional
phamacologically acceptable carriers, excipients,
diluents, etc. in accordance with per se known methods.
While the dosage varies with the subjects administration
routes, symptoms, etc., it is usually, when administered
to the above-mentioned mammals, about 0.1 mg/kg ~ 50 mg/kg
1~3'~
-29-
body weight, preferably about 0.5 mg/kg~ 20 mg/kg body
weight 1~ 3 times a day.
When Compound [I] is administered non-orally, for
examples as a suppository, about 5 mg ~ 10 mg/kg in te-ms of
Compound [I], 1~ 2 tlmes a day. As the injections, it is
desirable to use, in terms or Compound [I], about 0.1 mg/
kg~ 5 mg/kg 1~ 2 times a day.
For preparation of the above-mentioned compositions
for oral use such as tablet, a binding agent (e.g. hydroxy-
propyl cellulose, hydroxymethylpropylmethylcellulose, macro-
gol, etc.) a disintegrator (e.g. starch, carboxymethyl
cellulose calcium, etc.), an excipient (e.g. lactose, starch,
etc.), a lubricant (e.g. magnesium stearate, talc, etc.)
etc. may be suitably incorporated.
When a composition of non-oral use, for example,
an injectable preparation, an isotonizing agent (e.g.
glucose, D-sorbitol, D-mannitol, sodium chloride, etc.),
an antiseptic (e.g. benzylalcohol, chlorobulanol, methyl
para-hydroxybenzoate~ propyl para-hydroxybenzoate, etc.),
a buffer (e.g. phosphate buffer, sodium acetate buffer,
etc.), etc. may be suitably incorporated.
1~37Z8
- 30 -
Brief Description of the Drawing
Figure 1 shows the result of oxidation inhibitory
activity disclosed in Experiment 1.
3 7 ~ ~
-31-
The experiment examples, reference examples and
working examples are given below to illustrate the present
invention more specifically.
Experiment 1
Oxidation inhibitory activity determined with the use
of a stable radical:
In accordance with the method of ~. S. Brois [Nature,
181, 1199, 1958], the activity to reduce a stable
free radical, a, ~-diphenyl-~-picryl hydrazyl (DPPH),
was determined, which was used as an index of the
oxidation inhibitory activity. More concretely, a test
drug [i.e., the compound [I] wherein Rl=-(CH2)l 7C~3, R2=
OH, R3=H, which is sometimes referred to as "compound
(1-12)"] was added to 3 ml of 0.1 m~ DDPH ethanol so-
lS lution. Then, 20 minutes later, the absorbance at a
wavelength of 517 nm was measured with the use of a spec-
trophotometer. The difference in absorbance between
a sample solution and reference solvent [not more than 0.5%
of DMF] was taken as the reduction activity.
The results of the experiment are shown in Fig. 1,
where - - indicates the results with the above test
drug, - o - the results with vitamin E, and - ~ - the
results with vitamin C.
The above test drug was found to reduce DDPH at
1~37 ~8
-32-
the concentration of not less than 10 5M in a manner
dependent upon the amount used. Vitamins C and E showed
the activity equal to that of the test drug.
Experiment 2
Activity to inhibit lipid peroxide formation
in rat brain tissue homogenate:
(i) Method:
Male SD rats (12-weeks old) were subjected to
exsanguination under anesthesia with pentobarbital, then
the brain was excised. The brain tissue was homogenized
in a phosphate buffer solution (pH 7.4) to prepare a 5%
homogenate. After incubation of the homogenate at 37C
for 1 hour, the amount of lipid peroxides formed therein
was determined by thiobarbituric acid (TBA) ~ethod in
accordance with the report of Ohkawa et al. on Analytical
Biochemistry 95 351, 1979.
The test drug was added to the 5% homogenate before
incubation so as to make the final concentration be 10 5M.
The activity to inhibit the formation of lipid
peroxides was compared with that of the reference group
to which was added the solvent (DMSO), and shown by %
inhibition.
(ii) The results are shown in Table 1 below:
The activity to inhibit the formation lipid
peroxides varies with the length of the side chain, when
1~3-7~
-33-
the number (n) of the side-chain methylene groups in
the general formula [I] was changed in the range of
7-21. When n is in the range of 13-19, the correspond-
ing compounds showed higher activity, reaching 80% or
higher in the inhibitory activity, which is more potent
than that of vitamin E. As compared with the compound
having at the 3-position a methylene chain whose n
equals to 17, the compound (1-12) showed higher activity.
In the same experimental system, vitamin C rather promoted
the formation of lipid peroxides remarkably.
'7~
-34-
Table 1
ACtivities to inhibit lipid peroxide formation
in rat brain tissue homogenates(TBA method)
Inhibitory*
Compound [I] Effect (%)
R 2 = o H , R 3 = H . R I = - (C H 2)~ C H 3 -6.6+ 3.0
R 2 = o H , R 3 = H , R ' = - (C H 2)9 C H 3 40 0' 1.1
R 2 = o H , R 3 = H , R ' = - (C H 2)~1 C H 3 5~.7 - 26.5
R 2 = o H , R 3 = H , R ' = - (C H 2).3 C H 3 93.1+ 5.3
R2=OH,R3=H,RI=--(CH2)l~CH3 100.0_ o
R 2 = o H , R 3 = H , R ' = - (C H 2)~s C H 3 78.3 - 11.7
R 2 = o H , R 3 = H , R ' - - (C H 2)17 C H 3 88.6 + 6.8
R 2 = o H , R 3 = H , R ' = - ( C H 2)19 C H 3 9 5 . 4 - 4.6
R 2 _ O H , R 3 = H . R l= - (C H 2)2~ C H 3 38.1 ~ 16.6
Compound having a group at the 3-4~.4' 8.7
position**
Vitamin C -71.6--36.8
Vitamin E 44.9 11.7
Note) The concentration of each compound is 10 5M,
and the number of experimental examples of
each compound is 3. Inhibitory e~fects (%) are
shown by mean values ~standard error.
Note) . Compound having a group at the 3-position:
3'7Z~
HO
HO -
Ci'd3(CH2)~ 7 OH
Experiment 3
Effects to alleviate renal disorders in rats due
to Fe nitrilotriacetate:
(i) Method
Male SLC-Wistar rats (4-weeks old, 64~85 g) were
used. The animals were housed individually in metabolism
cages and allowed free access to feed and water. Body
weight, volume of urine and protein in urine (BIO-RAD
method) were determined every day, and occult blood reaction
was also examined ~abstick methodj. On the last day of
the experiment, the kidney was excised and weighed.
The animals were orally administered once daily
with test drugs or vehicles thereof (suspension in gum
arabic), and, 40~60 minutes later, were injected intra-
peritoneally with nitrilotriacetate (NTA) or Fe3 -NTA.
Fe3 -NTA was used in a form of mixture (1:4, molar ratio),
and the dosages were 5 mg/kg in terms of Fe3+ for 3 days
and successively 10 mg/kg for 5 days.
Test drugs were compound (1-12), vitamin C and vitamin E,
and the dosages were all 30 mg/kg.
(ii) Results
The results observed on the last day of the experiment
1~9 3'~
-36-
are shown in the following Tables 2 and 3.
In the animal groups administered with the vehicle,
renal disorders due to Fe3+-NTA were observed, and the
weight of kidney remarkably increased and, in most of
the animals, occult blood test was positive, and
remarkable increases in urine volume and protein in urine
were observed. In the groups administered with compound
(1-12), renal disorders were alleviated, thus, as compared
with the groups administered with vehicle, the weight of
kidney was significantly less, and the urine volume and
urinary protein were significatly less and, only
in half of the test animals, occult blood was detected.
Vitamin E showed substantially the same effects, but,
in more than half of the test animals,occult blood test
was positive. Vitamin C did not show significant effect
for alleviating renal disorders.
Table 2
Effects on renal disorders due to Fe3+-nitrilotriaCetate
(NTA)
.
Body Kidney Occult
Weight Weight Blood
Group n (g) (m8) Test
one~l 2 118 51 0 / 2-
V ehicle~6 86.6+ 3.7 68.2+ 2.1 5 / 6
Compound(1-12)6 95.5_ 3.0 56.5 + 2.0~ 3/ 6
Vitamin C 6 89.2' 4.1 64.5+ 1.7 5/ 6
Vitamin E 6 99.3 2.3 54.3+ 2.7~ 4 / 6
_
1~3~
Dosage of each test drug was 30 mg/kg, orally,
n: number of test animals
*1 None: Control animals not administered with Fe3 -NTA
*2 Vehicle: Gum arabic suspension
s
Table 3
Effects on renal disorders due to Fe3 -nitrilotriacetate (NTA)
Volume of Protein
urine in urine
Group n (ml/da~) (mg/daY)
~one 6 5.4_1.23.0_1.1
Vehicle 6 13.2'2.0li.l_l.9
Compound (1-12)6 7.4_1.3~ 8.1_2.1
Vitamin.C 6 10.3_1.710.7*2.4
Vitamin E 6 9.0+1.06.3+1.4
Dosage of each test drug was 30 mg/kg, orally.
n: number of test animals
None: Control animals not administered with Fe3 -NTA
Vehicle: Gum arabic suspension
Experiment 4
Action to inhibit ventricular arrhythmias
occurred during coronary artery occlusion-reperfusion in
rat hearts
(i) Method
Male SD rats (9~13 - weeks old, 250~370 g) were used.
1~37'~l~
-38-
The animals were subjected to thoractonomy under artificial
respiration while anesthesia was maintained by administer-
ing pentobarbital. The left anterior descending coronary
artery was ligated with silk thread for 5 minutes, then
the ligation was released to allow reperfusion, and
animals were observed for 10 minutes. By recording
standard limb lead ~ electrocardiograms,occurrence of
ventricular arrhythmias was examined.
The animals were administered,under non-anesthesia,with
test drugs as a gum arabic suspension at the dosaqe of
30 mg/kg at the time of about 90 minutes and of 20 mg/kg
at the time of about 45 minutes (total: 50 mg/kg), or
at the dosage of 10 mg/kg each (total: 20 mg/kg) at the
time of about 90 minutes and about 45 minutes prior to
closure of the coronary artery. The results are shown
in Table 4 in terms of the total amount of the dosage.
(ii) Results
When reperfusion was permitted after the closure
for S minutes of the left anterior descending coronary
artery, ventricular arrhythmias, typically exemplified
by occasionally occurring premature ventricular contractions
(PVCs), ventricular tachycardia (VT) and ventricular
fibrillation (VF), were observed. VT and VF were
paroxysmally repeated, or sustained VF resulted in
death.
'7'~
-39-
In the group administered with the vehicle, VF and
VT were observed in more than ~0~ of the animals, and the
durations were respectively about 80 and 20~30 seconds.
Among the animals, 10~25% were killed by occurrence of
sustained VF.
In the groups administered with 20 and 50 mg/kg
each of compound (1-12), occurrence of those arrhythmias
was suppressed significant~y and depending
on the dosages. Even when the arrhythmias occurred, the
period of time during which the symptom lasted was shortened. Conssquently
the mortality due to VF was low. Frequency of occasional
PVCs was around 10 times/minutes in the groups of the
vehicle, while, in the group administered with compound
(1-12), the frequency was less significantly.
On the other hand, no significant effects were observed by
or~l administration of vitamin C or E at the dosage of
50 mg/kg.
lZ~t3 7'~
-40-
Table 4
Effects on ventricular arrhythmiasobserved when reperfuslon was
permitted after closure of the coronary artery in rat hearts.
Ventricular fibrillation Ventricular tachycardia
Group Incidence Duration Incidence Duration Extrasystole Mortality
_
Control 7/8(8~) 83.9+27.5 7/8 (88) 31.8+15.0 10.8+3.5 2/8 (25)
Compound
(1-12)
50mg/kg 2/g~ (22) 1.2+ 0.8~ 2/9~ (22) 3.2_ 2.6~ 1.1+0.3**0/g ( 0)
Control 16/18 (89) 74.2+ 30.8 17/18 (94) 26.5+ 6.8 11.8_4.0 2/18(11)
Compound
(1 -12)
20mg/kg g/17~(53) 31.0+28.2 ll/17 (65) 10.2+ 3.2* 3.3+0.8~*1/17( 6)
Co~trol 17/18 (94) 74.1 ' 36.0 17/18 (94) 16.6l 4.4 7.3+1.7 3/18(11)
Vitamin C
50mg/kg 6/6 (100) 9.7+ 2.5 6/ 6(100) 19.0 3.0 5.1+ 1.0 0/ 6( 0)
Vitamin E
50mg/kg 6/10 (60) 43.4 - 36.0 I/10 (70) 22.3_ 9.7 I.O_4.1 1/10(10)
.
:P < 0.0~, :P < 0.01, as compared with Control Group
Incidences of ventricular fibrillation and ventricular
tachycardia are shown by the percentage of the number
of animals presenting the symptoms relative to the
number of animals subjected to the test, and the duration
of the symptoms was shown in average +SEM by seconds.
1~33'7~
-41-
Extrasystole is shown by the number of systole/min, and
the mortality is shown by the percentage of the number
of animals killed relative to the number of animals
subjected to the test.
Experiment 5
Inhibition of ischemic seizure due to ligation of
bilateral common carotid arteries in SHR rats
i) Method
Male S~R rats (22-weeks old, about 360 g) were used.
Under light anesthesia with ether, the animals were
subjected to midline incision at the neck and the
bilateral common carotid arteries were singled, then
ligated to cause cerebral ischemia. Thereafter, the
animals were allowed to awake from the anesthesia, and
the behavior was observed for about 4 hours. The animals
were orally administered with test drugs as a gum arabic
suspension 60 minutes before the ligation of the
bilateral common carotid arteries. The results are
shown in Table 5.
ii) Results
When the bilateral common carotid arteries were ligated
to cause cerebral ischemia, convulsion, an ischemic
seizure, was observed after about 150 minutes in the
vehicle group. The seizure was observed in about 90% of
the rats within 180 minutes. But, in the group orally
'7~
-42-
administered with compound (1-12) at a dosage of 100 mg/kg,
the appearance of the convulsion was significantly delayed
by about 40 minutes. The incidence of appearance of
the seizure within 180 minutes was significantly inhibited
to 20~.
Table 5
Activity to inhibit ischemic convulsive seizure observed
when bilateral common carotid arteries were ligated in
SHR rats
Ischemic convulsive seizure
Group n Time (min) Incidence ~
Vehicle 41 151 4 36/41 (87.8%)
Compound (1-12) 5 199 13~ 1/5* (20 %)
Compound (1-12): 100 mg/kg p.o.; Vehicle: Gum arabic
suspension
: Within 180 minutes
* : P< 0.05
1~37~
-43-
Experiment 6 Acute toxicity in mice
(i) Method
Male Crj-ICR mice (4-weeks old, 213 26 g) were
used. The animals, divided into groups, each consisting
of six mice, were administered orally with compound
(1-12) at the dosage of 300 or 1000 mg/kg.
Then, each group was housed in a cage, and observed for
24 hours. The test drugs were suspended in gum arabic,
and administered at the volume of 0.1 ml/10 g.
(ii) Results
In both groups administered with compound (1-12)
at the dosages of 300 and 1000 mg/kg, the state of
sedation and ptosis were observed, but both were recovered
within 3 hours. During 24-hour-observation, no test
lS animals of either group were killed.
1~93';'~
-44-
Reference Example 1
(1) L-Ascorbic acid acetonide (42 g, 0.19 mole) was
dissolved in a solvent mixture of dimethylformamide (100 mQ)
and hexamethylphosphoramide (100 mQ), and potassium carbonate
(32 g, 0.23 mole) was added to the solution, followed by
ice-cooling. A solution of chloromethyl methyl ether (18 g,
0.22 mole) in tetrahydrofuran (25 mQ) was added dropwise to
the mixture over the 20 minutes period. After stirring at
room temperature for 2.5 hours, water (200 mQ) was added
to the reaction mixture, to which 2N hydrochloric acid was
added to adjust to pH 5.0, followed by extraction with four
portions of ethyl acetate. The organic layer was washed with
water, dried and then concentrated under reduced pressure,
and the residue was subjected to silica gel column chromato-
graphy, followed by elution with isopropyl ether - ethyl
acetate (2:1). The eluate was concentrated, and the residue
was recrystallized from the same solvent system to give L-5,
6-O,O-isopropylidene-3-O-methoxymethylascorbic acid (46 g).
m.p. 93-94C.
Elemental analysis, for CllH16O7
Found : C, 50.84; H, 6.05%
Calcd.: C, 50.77; H, 6.20
(2) L-5,6-O,O-Isopropylidene-3-O-methoxymethylascorbic
acid (1.84 g, 7.1 mmole) was dissolved in dimethylsulfoxide
25 (10 mQ), and octadecyl iodide (2.68 g) and potassium
carbonate (1.0 g) were added to the solution, followed by
allowingthe reaction to proceed at 60C for 6 hours. After
1i~93 7, ~
-45-
the conclusion of the reaction, water (50 mQ) was added to
the reaction mixture, followed by extraction of the reaction
product with ethyl acetate. The organic layer was washed
with water, dried and concentrated under reduced pressure,
and the residue was subjected to silica gel column chromato-
graphy, followed by elution with isopropyl ether. Theeluate was concentrated, and the residue was recrystallized
from isopropyl ether - ethyl acetate to give L-5,6-0,0-
isopropylidene-3-o-methoxymethyl-2-0-octadecylascrobic acid
(R 1-11) (0.8 g). The physico-chemical properties are shown
in Table 6.
By the same procedure as in Reference Example 1, compounds
shown in Table 6 [(Rl-l) to (~1-33)] were prepared.
lZ~37~
-46-
~ O (5- and 6-positions form
~=~/ a isopropylidene)
CH3OCH2o ' '`O--Rl
Table 6
oundl R' I N M R
m.P.(C)
Rl~ -(C H2)s,Me ~0.87(3H,m),1.25(8H,m),1.34(3H,s),
¦ 1 1.37(3H,s),3.50(3H.s),4.09(5H,m),
I Oil ~4.51(lH,d,2Hz),5.40(2H,s)
Rl-2 -(C H2)7Me 0.85(3H,m),1.25(12H,s),1.34(3H,s),
1.37(3H,s),3.46(311,s),4.12(5H,m),
Oil 4.56(1H,d,2Hz),5.46(2H,s)
R1-3 -(C H2)8Me 0.85(3H,m),1.27(14H,m),1.33(3H,s),
1.36(3H,s),3.48(3H,s),4.12(5H,m),
Oil 4.57~1H,d,2Hz),5.45(2H,s)
_ . _
Rl-4 ¦-~C H2),OMe 0.87(3H,m),1.26(18H,m),1.33~3H,s),
1.37(3H,s),3.48~3H,s),4.12~5H,m),
Oil 4.56(1H,d,2Hz),5.46(2H,s)
Rl-5 -(C H2)" Me 0.85(3H,m),1.25(20H,m),1.34(3H,s),
1.37(3H,s),3.47(3H,s),4.12(511,m),
Oll 4.55(1H,d,2Hz),5.46(2H.s)
R1-6 -(C H2)l2Me 0.86(3H,m),1.25(22H,m),1.34(3H,s),
1.37(3H,s),3.48(3H,s),4.13(5H,m),
Oil 4.56(1H,d,2Hz), 5.45~2H,s)
1~93'7Z~
- 47
Table 6(continued)
~Compoun~ R ' N M R
m.p,(C)
R 1-7- (C H 2)1 3 M e 0.86(3H,m),1.25(24H,m),1.33(3H,s),
1.37(3H,s),3.45(3H,s),4.12(.5H,m),
Oil 4.56(1H,d,2Hz),5.46(2H,s)
_
R 1-8- (C H 2),~ M e 0.87(3H,m),1.24(26H,m),1.33(3H,m),
1.37(3H,s),3.49(3H,s),4.43(5H.m),
0il 4.56(1H,d,2Hz),5.44(2H,s)
_
R 1-9- (C H 2),s M e 0.87(3H,m),1.25(28H,m),1.34(3H,s),
1.38(3H,s),3.50(3H,s),4.11(5H,m),
44-45 4.56(1H,d,2Hz),5.44(2H,s)
._
R 1-10- (C H 2)1 ~ M e 0.85(3H,m),1.26(30H,m),1.33(3H,s),
1.36(3H,s),3.47(3H,s),4.11(5H,m),
0il 4.57(lH,d,2Hz),5.47(2H,s)
.
R 1-11- (C H 2)1 7 M e 0.85(3H,m),1.25(32H,m),1.33(3H,s),
1.37(3H,s),3.50(3H,m),4.12(5H,m),
50-52 4.57(lH,d,2Hz),5.47(2H,s)
__ __
R 1-12- (C H 2),9 M e 0.85(3H,m),1.25(36H,m),1.33(3H,s),
1.36(3H,s),3.47(3H,s),4.25(5H,m),
57-58 4.57(1H,d,2Hz),5.43(3H,s)
R 1-13- (C H 2)10 C O O M e 1.29(16H,m),2.30(2H,t,7Hz),3.51(3H.
, s),3.66(3H.s).4.11(3H,m),4.57(1H,d.
0il 2Hz),5.45(2H,s)
1;~9372~
- 48 -
Tab I e 6 (cont i nued)
ComPoun~ R ' I N,~I R
I propert ies
R 1 -14 - (C H 2)9 O H I I .30(20H.m),3.50(3H, s),3.51(3H.m), I
4.03(5H, m),4.51 (lH, d,2Hz),5.58(2H, s) ¦
Oil
R1-15 - Bz 1.34(3H,s),1.37(3H,s),3.38(3H,s).
4.06(3H, m~,4.50(1H, d,2Hz),5.05(2H,
Oi 1 s),5.17(2H, s),7.20~5H, s)
Rl-16 -(CH2)3Ph 1.31(3H,s),1.35(3H,s),1,97(2H,m),
2.67 (2H, m),3.42 (3H, s),4.06(5H, m),
Oi 1 4.50(1H, d,2Hz),5.36(2H, s),7.16(5H,
m)
R 1 -17 4 - B r - B z 1.34(3H, s),1.37 (3H, s),3.46(3H, s),
4.12(3H,m),4.58(1H,d,2Hz),5.09(2H,
Oi 1 s),5.32(2H, s),7.31(2H,d,7Hz),7.50
(2H, d,7Hz)
.
R 1 -18 4 - C 1 - B z 1.34(3H, s),1.38(3H, s),3.46(3H, s),
4.14(3H, m),4.56(1H, d,2Hz),5.10(2H,
Oi 1 s),5.31 (2H, s),7.30 (4H, s)
Y
R 1 -19 4 - Me - B z 1.34(3H, s),1.39(3H, s),2.33(3H, s),
3.43(3H, s),4.10(3H, m),4.56(1H, d,
Oi I 2Hz),5.10(2H, s),5.26(2H, m),7.16(2H,
d,8Hz),7.31(2H, d,8Hz)
-
3'721~3
-49-
Table 6(continLed)
.
¦CompoundR ' I .~' M R
j properties
R 1-20¦3 - M e - B z ¦ 1.34(3H.s).1.38(3H,s).2.34(3H,s).
3.43(3H.s),4.11(3H,m),4.54(1H,d,
Oil 2Hz),5.24(2H.s).5.24(2H,m).7.20(4H.
m)
_
R 1-214 - i P r- B z 1.23(6H.d,7Hz).2.90(1H,hep,7Hz),3.42
(3H,s),4.12(3H,m),4.56(1H,d,2Hz),
Oil 5.10(2H,s),5.25(2H,m),7.29(4H,m)
_ ._
R 1-224 - C O O M e- B z 1.33(3H,s),1.37(3H.s),3.46(3H,s),
3.90(3H,s),4.12(3H,m),4,57(1H,d,
Oil 2Hz),5.19(2H,s),5.32(2H,s),7.49(2H,
d,8Hz),8.04(2H,d,8Hz)
R 1-23 1.32~3H,t,7Hz),1.33(3H,s),1.37(3H,
-CH2 ~ ~ " COOEt s),3.44(3H,s),4.10(3H,m),4.23(2H,q,7
Hz),4,57(1H,d,2Hz),5.14(2H,s),5.31
Oil (2H,s),6.42(lH,d,16Hz),7.47(4H,m),
7.67(lH.d,16Hz)
R 1-24- C H 2 C H (P h)2 1.32(6H,s),2.46(2H,m),3.44(3H,s),
4.06(6H,m),4.53(1H,d,2Hz),5.36(2H,
Oil s),7.25(101~.S)
_
R 1-25- (C H 2)8 0 B z 1.34(12H,m),1.37(6H,s),3.46(2H,t,
7Hz),3.49(3H,s),4.09(5H,m),4.48(2H.
Oil s),4.54(1H,d,2Hz),5,42(2H,s),7.31(5H.
. s)
12937Z8
-50-
Table 6 (continued)
ICompoun~ R ' ~ R
¦ ~ properties
R 1-26~- C H 2 - C yclohe~yl 1.34(3H,s),1.38(3H,s),1.50(1lH,m),
3.50(3H,s),4.12(5H,m),4.56(1H.d,
IOil 2Hz),5.43(2H,s)
R 1-27- P henacyl 1.33(3H,s),1,37(3H,s),3.53(3H,s),
4.11(3H,m),4.61(1H,d,2Hz),5.54(2H,
Oil m),5.74(2H,m),7,53(3H,m),7.91(2H,m)
_ .
,. R 1-28 0.88(3H,m),1.35(14H,m),3.40(3H,s),
-CH2 ~ 0-(CH2)sCH3 3.91(3H,t,7Hz),4.08(3H.m),4.52(1H,d,
2Hz),5,01(2H,s),5.18(2H,s),6,80(2H,
Oil d,7Hz),7.27(2H,d,7Hz)
R 1-29 ~ 1,36(3H,s),1,38(3H,s),1,66(6H,m),
-(CH 2) ~ ~ 2,18(2H,m),3.48(3H,s),4,18(7H.m),
N 4.55(1H,m),5.40(2H,s),6.11(1H,t),
Oil 7,38(7H,m),8,42(1H,m),8,50(1H,m)
.
R 1-30 1.36(3H,s),1,44(3H,s),3.36(3H,s),
- C H 2 ~ 3,07(3H,m),4.51(1H,d),5.08(2H,s),
Oil 5,57(2H,s),7.45(7H,m)
.. ..
R 1~31- (CH2)~ y (CH2)7CH3 0.88(3H,m),1.30(22H,m),1,36(3H,s).
1,37(3H,s),2,00(4H,m),3,51(3H,m),
4.10(5H,m),4.57(1H,d),5.31(2H,m),
Oil 5.42(2H,s)
1~93~Z8
-Sl-
Table 6 (continued)
r
¦Compoundf R ' 1, N M R
properties
R 1-32¦ - C H 2 C O O M e 1.37(6H,s),3.52(3H,s),3.74(3H,g),
4.12(3H,m),4.54(1H,d),4.75(2H,s).
Oil ~ 5.49(1H,d),5.62(1H,d)
R 1-33 - (C H 2)4 C O O M e ¦ 1.37(6H,s),1.72(4H,m),2.35(2H,m),
¦ 3.49(3H,s),3.65(3H,s),4.10(5H,m),
Oil 15.36(2H,s)
B z:benzYl, M e:methyl,P h:phenyl,iP r:isopropyl,E t:ethyl
728
-52-
Reference Example 2
(1) L-ascorbic acid acetonide (21.6 g, 0.1 mole) was
dissolved in dimethylformamide (120 mQ), and the solution
was cooled with ice. To the solution were added potassium
carbonate (14 g, 0.1 mQ) and successively benzyl bromide
(11.2 mQ), followed by stirring at room temperature for 20
hours. After the conclusion of the reaction, water (100 mQ)
was added to the reaction solution. To the mixture was
added 2N hydrochloric acid to adjust to pH 5.0, followed by
extraction with two portions of ethyl acetate. The organic
layer was washed with water, dried (over magnesium sulfate)
and then concentrated under reduced pressure. The product
was subjected to silica gel column chromatography, and
elution was effected with isopropyl ether - ethyl acetate
(3:1). The eluate was concentrated, and then the residue
was recrystallized from isopropyl ether - ethyl acetate to
give L-5,6-O,O-isopropylidene-3-O-benzylascorbic acid (13 g,
40%), m.p. 105-106C.
(2) L-5,6-O,O-isopropylidene-3-O-benzylascorbic acid
(3.06 g, 0.01 mole) was dissolved in a solvent mixture of
dimethyl-sulfoxide (20 mQ) and tetrahydrofuran (15 mQ), and
potassium carbonate (1.5 g, 0.011 mole) was added to the
solution. Then, octadecyl iodide (3.83 g) was added to the
mixture, followed by stirring at room temperature for 18
hours. After the conclusion of the reaction, water (100 mQ)
was added to the reaction mixture, followed by extraction
with ethyl acetate. The organic layer was washed with water,
1~93'7~
-53-
dried (over magnesium sulfate~ and then concentrated under
reduced pressure. The residue was subjected to silica-gel
column chromatography, followed by elution with isopropyl
ether - ethyl acetate (10:1) to give L-5,6-0,0-
isopropylidene-3-0-benzyl-2-0-octadecyl-ascorbic acid
[compound (R2-7)] (3.8 g). The physico-chemical properties
are shown in Table 7.
By the same procedure as in Reference Example 2, compounds
shown in Table 7 [(R ~1) to (R2-12)] were prepared.
lZ9372~3
-54-
X 8~ /~_ ~5- and 6- positions form
an isopropylidene)
~-CH20' O-R'
Table 7
compound _ _ N M R
m.p.(C)
. _ . . .. ~
! R2-1 -(C H2)7Me 0.87(3H,m),1.27(12H,m),1.34(3H,s),
1.37(3H,s),4.06,(5H,m),4.54(1H,d,
Oil 2Hz),5.46(2H,s),7.36(5H,s)
_
R2-2 -(C H2)~Me 0.86~3H,m),1.26(16H,m),1.34(3H,s),
1.37(3H,s),4.08(5H,m),4.54(1H,d,
Oil 2H%),5.46(2H,s),7.37(5H,s~
R2-3 -(C H 2) ,~Me 0.&6(3H,m),1.24(26H,m),1.34(3H,s),
1.37(3H,s),4.08(5H,m),4.53(1H,d,
Oil 2Hz),5.46(2H,s),7.36(5H,s)
. _ ._
R2-4 -(C H 2) 1~ Me 0.86~3H,m),1.26(26H,m),1.34(3H,s),
1.37(3H,s),4.10(5H,m),4.53(1H,d,
Oil 2Hz),5.46(2H,s),7.36(5H,s)
. . _
R2-S -(C H 2) I sMe 0.85(3H,m),1.25(26H,m),1.34(3H,s),
1.37(3H,s),4.06(5H,m).4.54(1H,d,
Oil 2Hz),5.46(2H,s),7.37(5H,s)
. .
55~Z937Z~3
Table 7 (continued)
. . I
ComPoundl R I ~ lN M R
m.P.(~C) ¦
. _ _ I
R 2-6 - (C H 2)l~ M e 0.87(3H,m),1.25(28H,m),1.34(3H,s).
1.37(3H,s),4.08(5H,m),4.54(lH,d,
Oil 2Hz),5.46(2H,s),7.36(5H,s)
. ~
R 2-7 - (C H 2) ~ 7 M e 0.88(3H,m),1.26(32H,m),1.38(6H,s),
4.08(5H,m),4.51(lH.d,2Hz),5.43(2H,
44-45 s),7.29(5H,s)
! . . .
R 2-8 - (C H 2)~a M e 0.87(3H,m),1.24(36H,m),1.34(3H,s),
1.37(3H,s),4.06(5H,m),4.54(1H,d,
48-50 ¦ 2Hz),5.46(2H,s),7.36(5H,s)
...
R 2-9 - (C H 2)2, M e 0.87(3H,m),1.24(40H,m),1.34(3H,s),
1.37(3H,s),4.08(5H,m),4.53(1H,d,
60-61 2Hz),5.45(2H,s),7.36(5H,s)
R 2-10 ~Bz 1. 26(16H,m),1.35(3H,s),1.37(3H.s),
Me~OMe 2.14(3H,s),4.12(3H.m),4.51(1H,m),
sz 4.81(2H,m),4.88(2H,s),4.95(2H,s),
Oil 7.30(15Hz),
R 2-11 r~~ 1.37(6H,s),3.65(8H,m),4.10(3H,m),
- C H 2 C O N O 4.55(2H,m),4.81(2H,m),5.67(2H,s),
Oil 7.30(5H,s)
R 2-12 1.32(3H,s),1.36(3H,s),2.04(3H,s),
- C H 2 C O N ~ 3.60(3H,s),4.02(3H,m),4.23(3H.m),
0 i I COOMe 4.S3(3H,m),7.34(SH,m)
1~37~
-56-
Reference Example 3
(l) L-5,6-O,O-Isopropylidene-3-O-benzyl-2-O-octadecyl-
ascorbic acid (3.8 g) was dissolved in a solvent mixture of
tetrahydrofuran (40 mQ) and methanol (10 mQ), and 2N hydro-
chloric acid (20 mQ) was added to the solution, followed bystirring at 50C for 24 hours. After the conclusion of the
reaction, the reaction solution was concentrated under
reduced pressure, and the reaction product was extracted
with ethyl acetate. The organic layer was washed with water,
dried and then concentrated under reduced pressure, and the
residue was recrystallized from isopropyl ether - ethyl
acetate to give 3-O-benzyl-2-O-octadecylascorbic acid
[compound(R 3-7)] (2.6 g).
The physico-chemical properties are shown in Table 8.
(2) The compounds obtained in Reference Example 2 were
processed by a procedure analogous to the above to prepare
compounds [(~P~3-l) to ~3-12)], which are shown in Table 8.
!, .
lZ937Z~
HO
HO--
~=~=0
CH20' OR '
Table 8
¦Compounc _ I N M R
m.P. (C)
R3-1 -(CH2)7Me 0.87(3H,m),1.26(12H,m),4.00(5H,m),
Oi 1 4,66(.H, d,2Hz),5.45(2H, s),7.32(5H, s) ¦
R3-2 - (C H2)9Me 0.86(3H,m),1.25(16H,m),3.80(2H,m),
4.00 (3H, m),4.68(1H, d,2Hz),5.46(2H,
Oi 1 s),7.36(5H, s)
_ .
R 3-3- ( C H 2)1 3Me 0.86(3H, m),1.25(24H, m),3.80(2H, m),
4.00(3H,m),4.68(1H.d.2Hz).5.47(2H.
65-66 s),7.35(5H, s),
R 3-4 - (C H 2) I~Me 0.87(3H,m),1.23(26H,m) ,3.82(2H,m),
4.02(3H,m),4.68(1H,d,2Hz),5.47(2H,
62 -63 s),7.36(5H, s)
R 3 -5- ( C H 2)1 5Me 0.86(3H, m) .1.25(28H, m) .3.85(2H, m),
4.02 (3H , m) ,4.69 (1 H . d ,2Hz) ,5.47 (2H ,
71 -72 7.37(~H, s)
lZ93~721~3
- 58 -
Table 8 (continued)
Compound R ' I .~MR
m. P. (C) ¦
.
R3-6 - (C H2)l~Me 0.88(3H,m),1.25(30H,m),3.79(2H,m),
4.00(3H,m),4.67(1H,d,2Hz,),5.44(2H,
57 -58 s),7.33(5H, s)
._ . _ I
R3-7 - (C H2),7Me 0.87(3H,m),1.25(32H,m),3.80~2H,m),
4.01(3H,m),4.68(1H,m),5.46(2H,s),
l 75-76 ¦ 7.34(5H.s)
R3-8 - (C H2),9Me 0.86(3H,m),1.24(36H,m),4.00(5H,m),
4.68(1H, m),5.46(2H, s),7.36(5H, s),
77-78
. . ._
R 3 -9 - ( C H 2) 2 ~ M e 0.86(3H, m),1.25(40H, m),3.82 (2H, m),
4.02(3H,m),4.69(1H,d,2Hz),5.46(2H,
83 -85 s),7.36(5H, s)
.
R 3 -10 OBz 1.40(16H, m),2.13(3H, m),2.23(2H, m),
OM~Me
~ (CH2) lO~Me 3.91(6H, s),4.06(5H, m),4.90(2H, s),
Bz 4.97(2H,m),5.57(2H,m),7.30(15H,m)
Oi 1 -- -- ................ _
7 R3-11 ~_~ 3.37(4H,m),3.49(4H,m),3.90(2H,m),- C H 2 C O N O 4.20(1H, m),4.79(2H, m),4.89(1H,d),
Oil 5.56(1H,d),5.75(1H,d),7.40(5H,s)
I ,,
R 3 -12 2.04(4H, m),3.49(2H, m),3.60(3H, s),
- C H 2 C O N~ 4.02(3H, m) .4.23(111. m),4.53(3H. m),
O i l CooMe 7.34 (5H, s)
~ ~937~
- 59 -
Reference Example 4
L-5,6-O,O-Isoprpylidene ascorbic acid (52g, 0.24
mole) was dissolved in a mixture of tetrahydrofuran
(200 ml) and DMF(50 ml). Potassium carbonate (42 g,
0.3 mole) was added to the reaction mixture and the
mixture was stirred for 10 minutes at room temperature.
To the reaction mixture chloromethy ethyl e~her (27 ml,
0.3 mole) was added during 5 minutes under keeping
about 20C in an ice bath. After stirring for 4 hours
at room temperature, the reaction mixture was poured
onto water (300 ml), adjusted at pH 8 by adding 2N
hydrochloric acid and then extracted twice (400 rnl, 200 ml)
with ethyl acetate. The organic layer was washed with
water, dried and concentrated under reduced pressure.
The resulting crude product was purified with silica
gel column chromatography (300 g, Merck Ltd. Art 7734,
developing solvent; ethyl acetate: isopropyl ether = 1:2)
and then recrystallized from isopropyl ether (crystallized
out in refrigerator) to give 5,6-o,O-isopropylidene-
3-O-ethoxymethyl-(L~-ascorbic acid (40 g, 61~).
Reference Example 5
L-5,6-O,O-Isopropylidene-3-O-ethoxymethyl ascorbic
acid (13.6 g, 0.05 mole) and octadecyl iodide (20 g,
0.055 mole) were dissolved in a mixture of tetrahydrofuran
2~5 (200 ml) and DMSO (50 ml), and added potassium carbonate
(8 g, 0.06 mole) to the reaction mixture under stirring
at room temperature. After stirring the mixture for
~'~937Z~
-60-
3 hours at 50C, water (300 ml) was added to the mixture.
The reaction mixture was adjusted to pH 7 with 2N hydro-
chloric acid and extracted withisopropyl ether ~600 ml).
The organic layer was washed with water, dried and con-
centrated under reduced pressure. The resulting crudeproduct was purified with silica gelcolumn chromatography
(300 g, developing solvent; isopropyl ether) to give
5,6-O,O-isopropylidene-3-O-ethoxymethy-2-O-octedecyl-
(L)-ascorbic acid (15 g, 57 %). This compound did not
form any crystals at room temperature.
1293~;~Z8
- 61
Reference Example 6
(1) To a solution of 2-O-octadecyl-L-ascorbic acid (0.8 g,
2 mmole) in chloroform (20 m~) was added pyridine (1 mQ),
followed by adding dropwise benzoyl chloride (0.28 g,
2 mmole) at room temperature. The reaction mixture was
stirred for one hour, to which was added 2N hydrochloric
acid to acidify it. The organic layer was
washed with water and dried (over magnesium sulfate).
The solvent was evaporated off, and the product was recrystal-
lized from isopropyl ether - ethyl acetate to give 3-O-benzoyl-
2-C-octadecyl-L-agcorbic acid (0.6 g, 49~), ~.p. 68-69C.
C3H48O7 (Found: C,69.94; H,8.98~. Anal. Caicd: C,69.89;
H,9.08)
(2) By the same procedure as in the above, 2-O-hexadecyl-
L-ascorbic acid was ~ubjected to benzoylation to give 3-O-
benzoyl-2-O-hexadecyl-L-ascorbic acid, m.p. 77-78C.
C29H44O7 (Found: C,69.21; H,8.82~. Anal. Calcd.: C,69.02;
H,8.79)
~1
1~3'7~
-62~
Example 1
L-5,6-O,O-Isopropylidene-3-O-methoxymethyl-2-O-
octadecylascorbic acid (1.2 g) was dissolved in a solvent
mixture of methanol (30 mQ) and tetrahydrofuran (10 mQ),
and 2N hydrochloric acid (10 mQ) was added to the solution,
followed by stirring at 50C for 6 hours. The reaction
solution was concentrated under reduced pressure, and the
reaction product was extracted with ethyl acetate. The
organic layer was washed with water, dried (over magnesium
sulfate) and then concentrated under reduced pressure, and
the residue was recrystallized from isopropyl ether - ethyl
acetate to give 2-O-octadecylascorbic acid [compound (1-12)]
(0.82 g). This compound was also obtained from L-5,6-
O,O-isopropylidene-3-O-ethoxymethyl ascorbic acid by
hydrolysis mentioned above. The physico-chemical
properties are shown in Table 9.
Example 2
3-O-Benzyl-2-O-octadecylascorbic acid (2.1 g) was
dissolved in ethyl acetate (25 mQ), and 5% Pd-C (0.5 g)
was added to the solution to conduct catalytic reduction
under atmospheric pressure. The catalyst was filtered out,
and the filtrate was concentrated under reduced pressure.
The reaction product was recrystallized from isopropyl
ether - ethyl acetate to give 2-O-octadecylascorbic acid
25 [compound (1-12)] (1.5 g).
The physico-chemical properties are shown in Table 9.
1~93'72~
-63-
Example 3
Compounds [(1-1) to (1-38)] prepared by a procedure
similar to the above Examples 1 and 2 are set forth in
Table 9.
12937
- 64 -
HO O
HO ~?=~
HO `OR'
Table 9
¦Compound~ R ' Ex . No. I m. p. N M R
_ depended ¦ (C)
1 -1 --( C H 2) 5 M e I ¦ 100 -101 ¦ 0.88(3H . m) .1.32 (8H . m), 3.54 (2H . m),3.89 (3H, m), ¦
_ 4.70 (1 H . d, l Hz)
1 -2 --(C H 2)7Me I, 2 115-117 0.84(3H,m),1.26(12H.
m),3.53(2H . m),3.85(3H .
~ m),4.70(1H. d, lHz)
1 -3 - ( C H 2 ) 8 M e 1 , 2 122 -123 ¦ 0.86 (3H . m) .1.25 (14H .
m),3.54(2H,m),3.87(3H,
. m),4.71 (lH, d, lHz)
1 -4 --(C H 2)8Me 2 118-120 0.85(3H,m).1.24(16H.
m),3.43(2H . m),3.86(3H .
m) .4.72 (1 H . d . l Hz)
1 -5 --(C H 2) ,OMe 1 124 -125 ~ 0.86(3H.m) .1.24(18H.
m) .3.50 (2H . m) .3.87 (3H .
m),4.71 (1 H . d . lHz)
. 1 -6 - ( C H 2)11 Me 127 -128 1 0.85(3H, m) .1.24(20H . I
m),3.53(2H. m),3.91 (3H . ¦
m),4.72(1H.d.lHz)
1~372t~
-65-
Table 9 (continued)
Compoun~ R '~ Ex. ~o. m.p. ¦ N M R
l depended (C)
_
1-7 - (C H 2),2 M e I 129-130 0.85(3H,m),1.25(22H.m),
3.52~2H.m),3.91(3H,m),
_ __ l 4.72,(1H,d,lHz)
1-8 - (C H 2)l3 M e ¦ 1 ,2¦ 126-127 0.85(3H,m),1.25(24H,
m).3.51(2H.m),3.90(3H.
m),4.74(1H,d,lHz)
1-9 - (C H 2)l~ M e I .2126-127 0.85(3H,m),1.26(26H,
m),3.45(2H,m),3.86(3H,
_ m),4.73(1H,d,lHz)
1-10 - (C H 2) I s M e 1 ,2 128-129 0.86(3H,m),1.24(28H,
m),3.59(2H,m),3.94(3H,
m),4.75(1H,d,lHz)
1-11 - (C H 2) 1~ M e 1 , 2127-129 0.86(3H.m),1.27(30H,
m),3.54(2H,m),3.86(3H,
m),4.71(1H.d,lHz)
.......... _
1-12 - (C H ~),q M e 1 ,2127-128 0.85(3H,m),1.26(32H,
m),3.51~2H,m).3.91(3H.
m),4.75(1H,d,lHz)
1-13 - (C H 2)l8M e 1 . 2126-127 0.85(3H,m),1.23(36H,m),
3.45(2H.m),3.86(3H,m),
_ _ 4.70(1H,d,lHz)
129372l~
- 66 -
Table 9 (continued)
Compoundi R I Ex . ~o. I m. p. I N M R
~ depended I ( c~ !
1 -14 1 - ( C H 2)21 Me I, 2 125-127 1 0.86(3H.m),1.24(40H, m) ,¦
3.46(2H, m),3.86(3H, m), ¦
4.70 ( l H, s )
1 -15 - (CH2) . OC00Me I 78 - 79 ~ 1.26(16H, m),2.26(2H, t,
~ 7Hz),3.45(2H, m),3.54(3
¦ H, m),4.73(1H, s)
1-16 -(CH2)80H 1 73- 74 1.30(16H,m),3.45(4H,m), "
_ _ 3.80(3H, m),4.73(1H, s)
1-17 - Bz 1 126-127 3.44(2H,m),3.78(1H,m), ,
4.74(1H, s),4.96(2H, s)
7.38 (5H, m)
1-18 -(CH2)3Ph 107-108 1.92(2H,m),2.67(2H,m),
3.48(2H, m),3.77 (lH, m),
3.92(2H, t,7Hz),4.77(1H,
s),7,23(5H, m)
. ._
1 -19 4 - B r--B z 1 184 -185 3.45(3H, m),3,76(1H, m),
4.75(1H~ s) .4.92(2H, s)
7.36(2H, d,8Hz),7.54(2H,
d,8Hz)
l -20 4 - C 1--B z 1 174 -175 3.55 (2H , m) ,3.84 ( IH , m) ,
4.75(1H, s),4.98(2H, s),
7.38 (4H, m)
FROIl TRKEDR CHEM PRT 'a6.0~,09 12149
~ 3~7~
- 66A- ¦
Table 3 (contlnusd)
Co0pound R 'Ex . No. ~. ~ . N M R
depsndot (S~ )
1-21 4 - Mo- Bz 1 157-158 2.28(aH,s),3.45(aN,m),
8, ?5(1H,-),4.7a(1H, ~),
.00(2~,s),7.14(a~,t,
l~z),7. al (2H,1~z)
1-22 3-Ms-Bz 1 ~2- 3a 2.a0(a~,s),a.44(2~,~),
3.77(1~,m),4.75(1H,t,
lHz),4.~2(2H,o),1.20(~
. _ _ ~.~)
1 -23 4 - 1 P r - B z 1 118 -11~ 1.20(6H, d, IHz),3.87 (lH ,
hop,7Hz),3,45(2H, ~),
a . 7 ~ (lH, m),4.73 ~lH, 8),
4.71(2N, ~), I .27(4H,~)
1 -24 4 - COOY~ - Bz l 171 -172 8,44 (2~, ~),3.75 (2H, ~),
a. 84(a~,8),4,74(1~
5.0~(2~,s),7.55(2~,t,
_ 7~z),7.95(2H, d, l~z)
1-25 -C~COOEt I 158-1~0 1.28(3H, t,7Hz), a. 4B(2B,
~)~3~sl(l~l~)~4~22(a~
~,7Hz),4,78(1~, 8), 5 . 22,
(2~,9), B. a2(1~, d, la~z) .
~ 7. ~0 (2~, d,8Hz), I .62 (1~,
,; _ d,16Hz) .7.12 (2H, ~)
FROPl T~KED~ CHEIl PRT 93~zf~ 'a6.0~.29 121~0
- 66B-
Tabl~ 9 (continu~t)
~ompound __ Ex . No ~. p . N M R
tepend~t (~C )
. . _
1 -26-(CH,) . C~(Ph) . 1 12~ -13Q 2.37 (aH~ 3.4S(2~, ~),
~.78(3~ .17(1H, t,
7Hz), ~.74(1~, d, lBz),
7.2B(10H, ~) t
. .
1-27-(CH,),OCH,Ph 1 75- 78 1.20(12H,~),3.40(4H,~),
8.87 (3~, ),4.42 (2H, s),
4.74(1H, ~),7.29(5H, ~)
.
1-28-CH,-Cycloh~xyl 1 125-12B 1.25(6H,~),1.63(7~,~),
3,31(2~,~), a.62(3~, 8),
4,94(1H,~)
1 -29 - Phenacyl 1 14S -14B 3.43(2H, m), B .78(1H, ~),
~. 7~ 8) ~ 5, B3(aH. ~)
7. S8 (3H, ) .7.89 (2H . ~)
.. _ .
1 -30 ~~~ 1 13a-la~ O .88(a~.~) .1.3a(8~
--CH2~JO-(CH~ 3
.~5(2~,~),3,73(1~
3.9B(2H, t .7H2), ~ . I2~1H,
d, l~z), ~ .86(a~, B), ~ . 8
(2H, t,8Hz),7,32 (2~, t,
8Hz)
_. . .
1 -31 ~ 2 Oi l 3.5~ ),4. ~0(1~
-CH~CON O ~ .5B(2H, ~),4. B4(1H, t,
~,,~''- _...... ~_ ~
1~937Z8
- 67
Table 9 (contineed)
I
~Compo~ndl R 'I Ex. ~o. I m.P. I N M R
f depended I (C)
j -CH2CON ~ 2 ¦ Oil 1 1.95(4H,m),3.44(5H,m),
j 3.62(3H,s),4.35(1H,m~,
COOMe ,
i 4.60(1H,m),4.74(1,d,
l ~ 2Hz)
1-33-CH2 ~ ¦ 1 Oil 1 3.66(5H,m),4.74(1H,d,
2Hz),3.40(2H,m),7.43
_ _ L 1-
1-34 -(CH2)8~=J (CH2)tCH I ¦ 101-104 1 0.86(3H,m),1.25(22H,
3 m),l.98(4H,m),2.80(5H,
m),4.69(1H,d,2Hz),5.21 ¦
(2H,t,6Hz)
I 1-35 -CH2COOCH3 l I Oil 1 3.54(33,m),3.65(3H,
¦ s),3,88(5H,m),4.67
I (lH,d,2Hz)
1-36 -(CH2)~COOCH3 I Oil 1.70(4H.m),2.35(2H,
m).3.65(3H.s),3.88
i (5H,m),4.67(1H,d,
il l I
21~z)
1-37 1 O 2 Oil ~ 1.28(16H,m),2,12(3H,
Me ~ OMe l ¦
( 2)10 ~ OMe ~ s),2.57(2H,m),3.90
_ I (SH,m),3.85(6H,s)
. .. I
1~937Z8
68 -
Table 9 (continued)
i . ,
CompoundlR ' ¦ Ex. No. m.p. ¦ N M R
I depended (C)
._ ._ ~ I
1-38 .~ I Oil~1.46(6H,m).2.10(2H.m).
-(CH2)4 ~ 1 3.80(SH,m),4.63(1H,d,
~N 2Hz),6.10(1H,t,7Hz).
_ _ ~ 7.38(7H,m).8.45(2H.m)
I
Incidentally, the compound (1-37) was obtained by
subjecting a hydroquinone compound, prepared after conduct-
ing a procedure analogous to Example 2, to oxidation with
ferric chloride.
Example 4
(1) To a solution of 2-octadecyl-L-ascorbic acid (0.8 g,
2 mmole) in chloroform (20 mQ) were added pyridine ( 1 mQ)
and 4,4-dimethylaminopyridine (0.1 g), followed by adding
acetyl chloride (0.25 mQ) at room temperature. The reaction
lZ93721~
-69-
solution was stirred for 18 hours, then the organic layer
was washed with 2N hydrochloric acid, followed by washing
with water and drying. The solvent was evaporated off under
reduced pressure, and the product was recrystallized from
isopropyl ether - ethyl acetate to give 6-O-acetyl-2-O-
octadecyl-L-ascorbic acid (0.6 g, 65~), m.p. 117-118C.
C26H40O7 (Found: C,66.24; H,9.95%. Anal. Calcd: C,66.35;
H,9.85).
, (2) By a procedure analogous to the above, 2-O-pentadecyl-
L-ascorbic acid, 2-O-hexadecyl-L-ascorbic acid and 2-O-
octadecyl-L-ascorbic acid were respectively subjected to
acetylation, benzoylation, phenyl-acetylation, succinyla-
tion and nicotynoylation to give the following compounds.
(i) 6-O-Acetyl-2-O-pentadecyl-L-ascorbic acid, m.p. 112-
113C. C23H40O7 (Found: C,64.59; H,9.48%. Anal. Calcd:
C,64.46; H,9.41)
(ii) 6-o-Benzoyl-2-o-pentadecyl-L-ascorbic acid, m.p. 139-
140C. C28H4207(Found: C,68.36; H,8.78%. Anal.Calcd:
C,68.55; H,8.63)
(iii) 6-O-Phenylacetyl-2-O-pentadecyl-L-ascorbic acid,
m.p. 126-127C. C29H44O7 (Found: C,68.79; H,8.99%. Anal.
calcd: C,69.02; H,8.79)
(iv) 6-o-Acetyl-2-o-hexadecyl-L-ascorbic acid, m.p. 114-
115C. C24H42O7 (Found: C,65.02; H,9.46%. Anal.Calcd:
C,65.13; H,9.56)
1~93'72~3
-70_
(v) 6-O-Nicotynoyl-2-O-octadecyl-L-ascorbic acid
hydrochloride, m.p. 142-143C. C34H48NO7Cl (Found:
C,66.49; H,8.70; N,2.20~. Anal. Calcd: C,66.06; H,7.83;
N,2.27)
(vi) 6-0-(3~boxypropionyl)-2-O-tetradecyl-L,asoorbic acid,
m-p- 155-156C. C24H4009 (Fbund: 60.73; H, 8.66%. Anal.
Calcd: C, 60.99; H, 8.53)
(vii) 6-0-(3-Carboxypropionyl)-2-O~pentadecyl-L-asoorbic acid,
m-p- 156-157C. C25H4209 (F~und: 61.59; H, 8.87~. A~.
Calcd: C, 61.71; H, 8,70)
`I Viii) 6-0-(3-Carkoxypropionyl)-2~cr~Ky1-L-ascorbic acid,
m-p- 155-156C. C28H4809 (Found: 63.49; H,9.33%. Anal.
Calcd: C, 63.61; H, 9.15)
Example s
To a solution of 2-O-octadecyl-L-ascorbic acid
(0.8 g, 2 mmole) in chloroform (20 mQ) was added pyridine
(1 mQ). To the mixture was added dropwise acetyl chloride
(0.25 mQ) at room temperature. The reaction solution was
stirred for one hour, followed by washing with 2N
hydrochloric acid. The organic layer was washed with water
and dried. The solvent was evaporated off under reduced
pressure. The product was recrystallized from isopropyl
ether - ethyl acetate to give 3-O-acetyl-2-O-octadecyl-L~
ascorbic acid (0.8 g, 87%), m.p. 78-79C. C26H46O7
(Found: C,66.07; H,9.80%. Anal.Calcd: C,66.35; H,9.85)
Example_6
To a solution of 2-O-octadecyl-L-ascorbic acid
(0.8 g, 2 mmole) and phenylisocyanate (0.24 g, 2 mmole)
in chloroform (20 mQ) was added trichloracetic acid (0.1 mQ).
The mixture was heated at 60C for one hour, which was
1~3728
- 71 -
washed with water, dried and concentrated to give a
product. The product was recryslallized from isopropyl
ether - ethyl acetate to give 6-O-phenylcarbamoyl-2-O-
octadecyl-L-ascorbic acid (Q.75 g), m.p. 149-150C.
C31H49N07 (Found: C,68.14; H,9.08; N,2.7496. Anal. Calcd:
C,67.98; H,9.02; N,2.56).
Example 7
1) To a solution of sodium D-isoascorbate 120 g, 0.1
mole) in dimethylformamide (50 mQ) was added dropwise
benzyl bromide (12 mQ) . The mixture was heated at 50C for
4 hours. To the reaction solution was added water (100 mQ) .
The product was extracted with ethyl acetate. The organic
layer was washed with water, dried aNd ~oncentrated. Then,
the crude product was subjected to silica-gel chromatography
and developed with ethyl acetate to give 2-O-benzyl-D-
isoascorbic acid (10 g, 37%). This benzyl compound(10 g,
0.037 mole) was dissolved in a mixture of dimethyl
sulfoxide (40 mQ) and tetrahydrofuran (10 mQ) . The solution
was allowed to react with octadecyl iodide (14 g) in the
presence of potassium carbonate (5 g) at 50C for 2 hours.
To the reaction product, after cooling, was added water
(100 mQ), and the product was extracted with isopropyl
ether. The organic layer was washed with water, dried and
concentrated under reduced pressure. The concentrate was
subjected to silica-gel column chromatography, followed by
development with isopropYl ether: etnyl acetate (1:1).
Thus-obtained crude crystals were recrystallized from
hexane: isopropyl ether (1:1) to give 2-o-octadecyl-3-
1~93'7~1S
-72-
O-benzyl-D-isoascorbic acid (5 g, 26%), m.p. 62-63C.
C31H50O8 (Found: C,72.02; H,9.67%. Anal.Calcd: C,71.78;
H,9.72 )
2) 2-O-Octadecyl-3-O-benzyl-D-isoascorbic acid obtained
as above (3 g, 6.7 mmole) was dissolved in ethanol (50 mQ).
The solution was subjected to hydrogenation under atmos-
pheric pressure in the presence of 5% Pd-carbon (0.2 g).
Eighteen hours later, the catalyst was filtered off, and
the filtrate was concentrated under reduced pressure.
The concentrate was recrystallized from ethyl acetate to
give 2-O-octadecyl-D-isoascorbic acid (2 g, 80~), m.p.
103-104C. C24H44O6 (Found: C,67.45; H,10.46%. Anal.Calcd:
C,67.26; H,10.35).
Example 8
To a solution of 5,6-O,O-isopropylidene-3-O-
methoxymethyl-2-O-octadecyl-L-ascorbic acid (5 g, 10 mmole)
in tetrahydrofuran (20 ml) was added 1,8-diazabicyclo[5,4,0]-
7-undecene (3 mQ). The mixture was stirred at 50C for 2
hours. To the reaction mixture, after cooling, was added
ethyl acetate (40 mQ). The whole mixture was washed twice
with 2N hydrochloric acid, followed by washing with water,
drying and concentration under reduced pressure. The con-
centrate was stirred at 60C for 6 hours in a mixture
of ethanol (40 ml) and 2N hydrochloric acid (20 ml). ~-
The reaction solution was concentrated under reduced pressure,and the product was dissolved in ethyl acetate, washed with
water, dried and concentrated. The crude product thus
lZ937~
-73-
obtained was recrystallized from isopropyl ether to give
2-O-octadecyl-5-dehydroxyascorbic acid (2 g, 51%), m.p.
114-il5C. C24H42O5 (Found: C,70.24; H,10.42%. Anal. Calcd:
C,70.21; H,10.31).
2-O-Octadecyl-5-dehydroxyascorbic acid obtained as above
(0.4 g, 1 mmole) was dissolved in ethanol (10 mQ). To the
solution was added 5% Pd-carbon (0.2 g), and the mixture
was stirred in hydrogen atmosphere for 4 hours under normal
pressure. After completion of the reaction, the catalyst
was filtered off, and the filtrate was concentrated under
reduced pressure. The concentrate was recrystallized from
isopropyl ether - hexane to give the desired d,Q-2-0-
octadecyl-5-deoxyascorbic acid (0.2 g), m.p. 83-84C.
C24H44S (Found C,69.33; H,10.74%. Anal. Calcd:
C,69.86; H,10.75).
1 2~ 3
-74-
Example 9
By using the following ingredients, tablets are
prepared by ~ se conventional means.
Compound (1-12)
[Compound [I] wherein
(CH2) 17CH3
R =OH, R =H] 50 mg
Corn starch 90 mg
Lactose 30 mg
Hydroxypropyl cellulose L 25 mg
Magnesium stearate 5 mg
lS Total 200 mg
(per tablet)
Dosage is 1-3 tablets/adult after each meal (three times/
day).
lZ~37~
Example 10
By using the following ingredients, tablets are
prepared by per se conventional means.
Compound (1-9)
[Compound [I] wherein
R =(CH2)14CH3,
R =OH, R =H] 60 mg
Corn starch 80 mg
10 Lactose 30 mg
Hydroxypropylcellulose L 25 mg
Magnesium stearate 5 mg
Total 200 mg
lS Dosage is 1-3 tablets/adult after each meal (three times/day).
1~3'72~
- 76 -
Example 11
.
(1) To a solution of 2-O-octadecyl-L-ascorbic acid (0.8 g,
2 mmol) in acetone(50 mQ) was added p-toluenesulfonic acid (50 mg).
The mixture was stirred at room temperature for 6 hours.
5 To the reaction solution was added sodium hydrogencarbonate
(100 mg), which was then concentrated under reduced pressure
The resulting crude crystals were recrystallized from
diisopropyl ether (IPE) to give 2-O-octadecyl-5,6-O,O-
isopropylidene-L-ascorbic acid (0.8 g, 91%), m.p. 81-82~C.
10 (2) 2-O-Dodecyl-L-ascorbic acid and 2-O-hexadecyl-L-ascorbic
acid were respectively subjected to a reaction analogous to
the above to give the compounds shown below, respectively.
(i) 2-O-Dodecyl-5,6-O,Q-isopropylidene-L-ascorbic
acid, m.p. 83-84C
15 (ii ) 2-O-Hexadecyl-5,6-O,O-isopropylidene-L-ascorbic acid,
m.p. 85-86C
Example 12
(1) To a solution of 2-O-hexadecyl-L-ascorbio acid (0.8 g,
2 mmol) and cyclohexanone (0.3 g) in toluene (50 mQ) was
20 added p-toluenesulfonic acid (50 mg). While the mixture was refluxed, the
water then produced was separated. The reaction solution,
after cooling, was washed with an aqueous solution of saturated
sodium hydrogencarbonate, followed by drying and concentra-
tion under reduced pressure to give crude crystals, which
25 were recrystallized from IPE to give 2-O-hexadecyl-5,6-
O,O-cyclohexylidene-L-ascorbic acid (0.6 g, 84%), m.p.
80-81C.
'7~~
(2) 2-0-Dodecyl-L-ascorbic acid was subjected to a`
reaction analogous to the above to give the following
compound.
(i) 2-0-Dodecyl-5,6-0,0-cyclohexylidene-L-ascorbic acid,
m.p. 85-86C.
